Search results
Bellerophon Therapeutics (BLPH) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks via Yahoo Finance· 1 year agoBellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from...
Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?
Zacks via Yahoo Finance· 11 months agoThe Medical group has plenty of great stocks, but investors should always be looking for companies...
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size
Zacks via Yahoo Finance· 2 years agoBellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse...
Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know
Zacks via Yahoo Finance· 10 months agoBellerophon Therapeutics (BLPH) closed at $0.68 in the latest trading session, marking a -1.93% move...
Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoBellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being...
Bellerophon Therapeutics (NASDAQ:BLPH) delivers shareholders fantastic 978% return over 1 year,...
Simply Wall St. via Yahoo Finance· 11 months agoActive investing isn't easy, but for those that do it, the aim is to find the best companies to buy,...
Bellerophon Therapeutics Shares Gained Over 200% Today
Benzinga via Yahoo Finance· 1 year agoBellerophon Therapeutics Inc (NASDAQ: BLPH) entered into a license agreement for the development and...
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails
Zacks via Yahoo Finance· 11 months agoBellerophon BLPH stock declined almost 87% on Jun 5. This occurred soon after the company announced...
When Will Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Turn A Profit?
Simply Wall St. via Yahoo Finance· 1 year agoWe feel now is a pretty good time to analyse Bellerophon Therapeutics, Inc.'s (NASDAQ:BLPH) business...
Why Are Bellerophon Shares Jumping Today?
Benzinga via Yahoo Finance· 2 years agoThe FDA has accepted Bellerophon Therapeutics Inc's (NASDAQ: BLPH) proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial...
